

Name of the Issuer:		Invicta Diagnostic Limited	Last updated on	13-Aug-25
1	Type of Issue (IPO / FPO)			
2	Offer Size (Rs. Cr)*		28.12	
	- Fresh Issue Size (Rs. Cr)		28.12	
	-Offer for Sale Size (Rs. Cr)		-	
	*Source: Prospectus dated December 04, 2025 and Final Post issue report dated December 10, 2025.			
3	Grade of issue along with name of the rating agency			
	Name	Not Applicable		
	Grade	Not Applicable		
4	Subscription Level (Number of times)		6.46*	
	Source: Final Post issue report dated December 10, 2025			
	*The above figure is after technical rejections			
5	QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges			
	Particulars			%
	(i) allotment in the Offer <sup>(1)</sup>			10.60%
	(ii) at the end of 1st Quarter immediately after the listing			0.00%
	(iii) at the end of 1st FY (March 31, 2026)*			Not Available
	(iv) at the end of 2nd FY (March 31, 2027)*			Not Available
	(v) at the end of 3rd FY (March 31, 2028)*			Not Available
	*QIB Holding not disclosed as reporting for the relevant fiscal year has not been completed.			
	(1) Source: Basis of Allotment			
6	Financials of the issuer (standalone)			
	(In Rs. Lacs)			
	Parameters	1st FY (March 31, 2026)*	2nd FY (March 31, 2027)*	3rd FY (March 31, 2028)*
	Income from operations	Not Available	Not Available	Not Available
	Net Profit for the period	Not Available	Not Available	Not Available
	Paid-up equity share capital	Not Available	Not Available	Not Available
	Reserves excluding revaluation reserves	Not Available	Not Available	Not Available
	*Financials not disclosed as reporting for the relevant fiscal year has not been completed.			
7	Trading Status in the scrip of the issuer			
	Company's Equity Shares are listed on National Stock Exchange of India Limited (NSE EMERGE)			
	The Shares have not been suspended or delisted.			
	Particulars			Status
	(i) at the end of 1st FY (March 31, 2026)*			Not Available
	(ii) at the end of 2nd FY (March 31, 2027)*			Not Available
	(iii) at the end of 3rd FY (March 31, 2028)*			Not Available
	*Trading status not disclosed as the relevant fiscal year has not been completed.			
8	Change in Directors of issuer from the disclosures in the offer document			
	Particulars	Name of the Director	Appointed / Resigned	
	(i) at the end of 1st FY (March 31, 2026)*	-	-	
	(ii) at the end of 2nd FY (March 31, 2027)*	-	-	
	(iii) at the end of 3rd FY (March 31, 2028)*	-	-	
	Source: Stock Exchange Filings			
	* Changes in Directors of Issuer not updated as the relevant financial years have not been completed			

**9 Status of implementation of project/ commencement of commercial production**

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

**10 Status of utilization of offer proceeds**

(i) as disclosed in the offer document

(Rs. Crore)

<b>Objects of the Fresh Issue</b>	<b>Amount</b>
Funding capital expenditure for purchase of medical equipment towards establishment of five new diagnostic centres in Maharashtra; and	21.11
General corporate purposes#	4.07
<b>Total</b>	<b>25.18</b>

Source: Prospectus dated December 04, 2025

(ii) Actual utilization

(Rs. Crore)

<b>Objects of the Fresh Issue</b>	<b>Amount</b>
Funding capital expenditure for purchase of medical equipment towards establishment of five new diagnostic centres in Maharashtra; and	Not Available
General Corporate Purpose	Not Available
<b>Total</b>	<b>Not Available</b>

(iii) Reasons for deviation, if any

Not applicable

**11 Comments of monitoring agency**

(a) Comments on use of funds	Not Available
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	Not Available
(c) Any other reservations expressed by the monitoring agency about the end use of funds	Not Available

**12 Pricing Data**

Offer Price (Rs.):	85
Designated Stock Exchange:	NSE
Listing Date:	08-Dec-25

Price parameters	At close of listing day (December 08, 2025)	At close of 30th calendar day from listing day ( January 07, 2025) <sup>(1)</sup>	At close of 90th calendar day from listing day (February 06, 2025) <sup>(2)</sup>	As at the end of 1st FY after the listing of the issue (March 31, 2026)		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE	96.00	Not Available	Not Available	Not Available	Not Available	Not Available
NIFTY 50	25,960.55	Not Available	Not Available	Not Available	Not Available	Not Available

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2027) <sup>(3)(4)</sup>			As at the end of 3rd FY after the listing of the issue (March 31, 2028) <sup>(3)(4)</sup>		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
NIFTY 50	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

\*Being index of NSE, the designated stock exchange

Note:

(1) 30th calendar day shall be taken as listing date plus 29 calendar days.

(2) 90th calendar day shall be taken as listing date plus 89 calendar days.

(3) High and Low based on intra day prices

(4) Pricing data not disclosed as the relevant fiscal year has not completed

(5) In case of any reporting day falling on a holiday, previous trading day prices has been disclosed.

**13 Basis for Offer Price-**

Accounting ratio	As disclosed in the offer document <sup>(1)</sup>	At the end of 1st FY (March 31, 2025)	At the end of 2nd FY (March 31, 2026) <sup>(2)</sup>	At the end of 3rd FY (March 31, 2027) <sup>(2)</sup>
	<b>Issuer:</b>	<b>5.86</b>	<b>5.86</b>	<b>Not Available</b>
	<b>Peer Group:</b>			
EPS	Vijaya Diagnostic Centre Limited	13.95	13.95	Not Available
	Krsnaa Diagnostics Limited	24.04	24.04	Not Available
	<b>Issuer:</b>	<b>14.51</b>	<b>14.51</b>	<b>Not Available</b>
	<b>Peer Group:</b>			
Price to Earnings Ratio (P/E)	Vijaya Diagnostic Centre Limited	72.22	72.22	Not Available
	Krsnaa Diagnostics Limited	34.39	34.39	Not Available
	<b>Issuer:</b>	<b>16.15</b>	<b>16.15</b>	<b>Not Available</b>
	<b>Peer Group:</b>			
NAV	Vijaya Diagnostic Centre Limited	77.86	77.86	Not Available
	Krsnaa Diagnostics Limited	272.54	272.54	Not Available
	<b>Issuer:</b>	<b>36.25%</b>	<b>36.25%</b>	<b>Not Available</b>
	<b>Peer Group:</b>			
RoNW(%)	Vijaya Diagnostic Centre Limited	17.99%	17.99%	Not Available
	Krsnaa Diagnostics Limited	8.79%	8.79%	Not Available

**Notes:**

(1) Sourced from Prospectus dated December 04, 2025

(2) Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above are/shall be calculated as follows:

(i) Earnings per Equity Share are computed in accordance with Accounting Standard 20 "earnings per Share" notified by the Companies (Accounting Standards) Rules, 2006.

(ii) NAV per share - Net asset value per Equity Share represents net worth as at the end of the Fiscal divided by the number of Equity Shares outstanding at the end of the Fiscal

(iii) P/E - Closing Market Price as of relevant fiscal year end / Basic EPS for the Fiscal

(iv) RoNW - Return on net worth (%) is net profit attributable to equity shareholders divided by net worth for the Fiscal

**14 Any other material information**

Date of disclosure to Designated Stock Exchange	Announcement
Not Applicable	Not Applicable

**Disclaimer:**

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by Socradamus Capital Private Limited ("Socradamus") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012. This information is gathered from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") and together with the BSE, the "Stock Exchanges"), as applicable, from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.